moexipril methyl ester

Moexipril methyl ester is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor.

Moexipril hydrochloride (Moexipril HCl) 是一种有口服活性的，不含巯基的血管紧张素转化酶抑制剂，可治疗高血压和充血性心力衰竭。

Moexipril 是口服具有活力的血管紧张素转换酶 (ACE) 抑制剂。Moexipril 易于透过脂质膜，靶向血浆和组织ACE，改善内皮功能障碍，具有神经保护活性，能够用于研究心血管疾病。

Moexipril-d5 intended for use as an internal standard for the quantification of moexipril by GC- or LC-MS. Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat. It is converted to moexiprilat in vivo by side chain ester hydrolysis. Moexipril inhibits ACE in a cell-free assay (IC50 = 2.7 µM for the rabbit enzyme). It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5 and PDE4D5, respectively). Moexipril (0.1-30 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.1 It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg/kg.